Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Sinco Pharmaceuticals Holdings Ltd. ( (HK:6833) ).
Sinco Pharmaceuticals Holdings Ltd. reported a 21.7% decrease in revenue to RMB1,195.8 million for the first half of 2025, primarily due to a decline in pharmaceutical sales amid intensified market competition. Despite the revenue drop, the company managed a slight increase in net profit to RMB24.4 million, attributed to reduced overall expenses, including selling, distribution, and administrative costs.
The most recent analyst rating on (HK:6833) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Sinco Pharmaceuticals Holdings Ltd. stock, see the HK:6833 Stock Forecast page.
More about Sinco Pharmaceuticals Holdings Ltd.
Sinco Pharmaceuticals Holdings Ltd. is a company incorporated in the Cayman Islands, primarily engaged in the pharmaceutical industry. It focuses on the production and sale of pharmaceutical products and also offers medical beauty services.
Average Trading Volume: 280,181
Technical Sentiment Signal: Buy
Current Market Cap: HK$496M
Find detailed analytics on 6833 stock on TipRanks’ Stock Analysis page.